BiotechTubeBiotechTube
Home/Pipeline/Undisclosed Cell Therapy

Undisclosed Cell Therapy

Undisclosed

Pre-clinicalEarly-stage

Key Facts

Indication
Undisclosed
Phase
Pre-clinical
Status
Early-stage
Company
Immix Biopharma

About Immix Biopharma

Immix Biopharma is a public company (NASDAQ: IMMX) focused on developing transformative cell therapies for serious diseases, starting with AL Amyloidosis. Its core innovation is the N-GENIUS platform, which produces sterically-optimized CAR-Ts designed to overcome neurotoxicity—the major barrier to CAR-T adoption. The company has achieved key milestones including FDA Breakthrough Therapy Designation for NXC-201, strong Phase 1b/2a clinical results (92% ORR), and recently closed a $100 million underwritten offering to advance its pipeline.

View full company profile

Therapeutic Areas

OncologyHematologyAutoimmune DiseasesRare Diseases

Other Undisclosed Drugs

DrugCompanyPhase
ASPEN Study ProgramInsmedPhase 3
ARISE Study ProgramInsmedPhase 3
MGL-2086Madrigal PharmaceuticalsPhase 1
Innovative Proprietary/Licensed ProductsLaboratorios Farmaceuticos RoviVarious
Undisclosed Partnered ProgramSepternaDiscovery
HTL0039732Nxera PharmaPreclinical
LYT-310PureTech HealthPreclinical
Bispecific (Undisclosed)MacroGenicsPreclinical
Sec61 Portfolio AssetsKezar Life SciencesPreclinical
WTX-518Werewolf TherapeuticsPreclinical
WTX-712Werewolf TherapeuticsPreclinical
Measovir®-based Prophylactic Vaccine (with Unither)OncovitaResearch/Pre-clinical